Sharon Solomon

Medicine & Life Sciences

1. Macular Degeneration 100%
2. Optical Coherence Tomography 88%
3. Macular Edema 87%
4. Eye 67%
5. Ranibizumab 59%
6. Vascular Endothelial Growth Factor A 56%
7. Retinal Vein Occlusion 52%
8. Visual Acuity 51%
9. Retina 35%
10. Choroidal Neovascularization 35%
11. Diabetic Retinopathy 35%
12. Geographic Atrophy 30%
13. Ocular Vision 30%
14. Eye Diseases 24%
15. Bevacizumab 23%
16. Deep Learning 20%
17. Multiple Sclerosis 20%
18. Light Coagulation 19%
19. Endothelial Growth Factors 18%
20. Injections 15%
21. Photochemotherapy 14%
22. Therapeutics 12%
23. Retinal Detachment 12%
24. Angiography 12%
25. Edema 12%
26. Retinal Perforations 12%
27. lifitegrast 11%
28. Confidence Intervals 11%
29. Verteporfin 11%
30. Lasers 11%
31. Fluorescein Angiography 9%
32. pegaptanib 9%
33. Retinal Neovascularization 9%
34. White Dot Syndromes 9%
35. Uveomeningoencephalitic Syndrome 8%
36. Systematic Reviews 8%
37. Retinal Vessels 8%
38. Angiopoietins 8%
39. Flavoproteins 8%
40. Natural History 7%
41. Randomized Controlled Trials 7%
42. Health Care Outcome Assessment 7%
43. Odds Ratio 7%
44. Eye Manifestations 7%
45. Lymphocyte Function-Associated Antigen-1 7%
46. Angiogenesis Inducing Agents 7%
47. atezolizumab 7%
48. aflibercept 7%
49. Succinate Dehydrogenase 7%
50. Retreatment 7%